← ALUMIS INC. (ALMS) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
ALUMIS INC. (ALMS)
Pharmaceutical Preparations · market cap $183M · as of 2026-07-12
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-12 (est.)
Earnings
Pipeline
3
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Alumis Inc. (ALMS) is a clinical-stage pharmaceutical company with a market cap of approximately $183M focused on dermatology, with its lead asset ESK-001 in Phase 3 development for plaque psoriasis. The company reported $24M in revenue and a net loss of $243M in 2025, against $386M in R&D spend, signaling heavy investment ahead of key readouts. A critical concern is the reported cash runway of only ~2.2 months, placing near-term financing risk at the center of the investment debate.
The catalyst path
- 2026-11-12 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Open-Label ESK-001 | Phase 3 | Plaque Psoriasis |
| ESK-001 | Phase 3 | Plaque Psoriasis |
| Apremilast | Phase 3 | Plaque Psoriasis |
Price & technical context
3-month
-72.8%
6-month
-68.3%
12-month
+80.7%
52-wk range
$3.96–$30.30
vs 50-day MA
-60.3%
vs 200-day MA
-67.5%
Realized vol
132.0%
Max drawdown
-78.4%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for ALMS (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.